Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195630 | 1.00 | NPSR1 (0.40) | NPSR1CA1CA2TSHRMAPT | |
| SCHEMBL4195633 | 1.00 | NPSR1 (0.40) | NPSR1CA1CA2TSHRMAPT | |
| SCHEMBL4195629 | 1.00 | NPSR1 (0.40) | NPSR1CA1CA2TSHRMAPT | |
| SCHEMBL4205642 | 0.90 | NPSR1 (0.42) | NPSR1TSHRMAPTRAB9AALOX15 | |
| SCHEMBL4205647 | 0.90 | NPSR1 (0.42) | NPSR1TSHRMAPTRAB9AALOX15 | |
| SCHEMBL4205643 | 0.90 | NPSR1 (0.42) | NPSR1TSHRMAPTRAB9AALOX15 | |
| SCHEMBL4209647 | 0.90 | NPSR1 (0.42) | NPSR1TSHRMAPTRAB9AALOX15 | |
| SCHEMBL4199779 | 0.83 | NPSR1 (0.44) | NPSR1CA1CA2MAPTALOX15 | |
| SCHEMBL4199787 | 0.83 | NPSR1 (0.44) | NPSR1CA1CA2MAPTALOX15 | |
| SCHEMBL4199790 | 0.83 | NPSR1 (0.44) | NPSR1CA1CA2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | claimed |
| EP-1768952-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Warner-Lambert Company LLC (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006008612-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-26 | — | — | WO | claimed |
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| EP-1768952-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Warner-Lambert Company LLC (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008612-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | SCN2A, SCN1A, ORAI2 | NPSR1 1807/4885CA1 646/4885CA2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.